Data from the pivotal GEOMETRY mono-1 phase II study show treatment with Tabrecta (capmatinib, formerly INC280) resulted in positive overall response rates among adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to skipping of MET exon 14. Positive duration of response was also observed.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
